Skip to main content
Evidence Snapshot

NTERA-2-cl-D1

CHEMBL614206 CELL-LINE Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614206
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NTERA-2-cl-D1 as ChEMBL target CHEMBL614206. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NTERA-2-cl-D1
CELL-LINE · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL614206
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why NTERA-2-cl-D1 matters

As of 2026-09-13

NTERA-2-cl-D1 is reviewed as NTERA-2-cl-D1; the current evidence base includes 32 approved drugs, 154 compounds, and 51 assays, with lead potency reaching pChEMBL 10.7.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 32 approved drugs, 154 compounds, and 51 assays for this target. The dominant activity type is IC50. CHEMBL105 is the current potency anchor at pChEMBL 10.7.

Use CHEMBL105 as the tractability anchor when discussing potency (pChEMBL 10.7).

Activity source · ChEMBL 36 via Core Engine
32 approved pChEMBL 10.7
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why NTERA-2-cl-D1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

154
Total Compounds
51
Total Assays
32
Approved Drugs
IC50: 152.0, EC50: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL105
 10.7 IC50 Approved
No preferred name
CHEMBL325041
 9.6 IC50 Clinical
No preferred name
CHEMBL65
 9.6 IC50 —
No preferred name
CHEMBL96926
 9.4 IC50 —
No preferred name
CHEMBL413
 9.3 IC50 Approved

Approved Drugs

Structure Compound First Approval
MIDOSTAURIN
CHEMBL608533
 2017
TEMSIROLIMUS
CHEMBL1201182
 2007
DASATINIB
CHEMBL5416410
 2006
SIROLIMUS
CHEMBL413
 1999
GEMCITABINE
CHEMBL888
 1996
DOCETAXEL
CHEMBL3545252
 1995
VINORELBINE
CHEMBL553025
 1994
PACLITAXEL
CHEMBL428647
 1992
ETOPOSIDE
CHEMBL44657
 1983
MITOMYCIN
CHEMBL105
 1981
DOXORUBICIN
CHEMBL53463
 1974
CYTARABINE
CHEMBL803
 1969
VINBLASTINE
CHEMBL159
 1965
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T21:25:05Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614206